K Dass Pharma Distributors Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 2.00 M
- Company Age 33 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.44 M
- Revenue Growth -9.75%
- Profit Growth -10.28%
- Ebitda -9.09%
- Net Worth 4.11%
- Total Assets 3.66%
About K Dass Pharma Distributors
K Dass Pharma Distributors Pvt Ltd (KDPDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 14 March 1991 and has a history of 33 years and ten months. Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.00 M.
The company currently has active open charges totaling ₹0.44 M.
Mansukh Tulsani, Pavan Tulsani, and Sunny Tulsani serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U99999MH1991PTC060755
- Company No.
060755
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Mar 1991
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at K Dass Pharma Distributors?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mansukh Tulsani  | Director | 14-Mar-1991 | Current |
| Pavan Tulsani | Director | 16-Aug-1998 | Current |
| Sunny Tulsani | Director | 23-Apr-2012 | Current |
Financial Performance of K Dass Pharma Distributors.
K Dass Pharma Distributors Pvt Ltd, for the financial year ended 2023, experienced Minor drop in revenue, with a 9.75% decrease. The company also saw a substantial fall in profitability, with a 10.28% decrease in profit. The company's net worth moved up by a moderate rise of 4.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of K Dass Pharma Distributors?
In 2023, K Dass Pharma Distributors had a public holding of 20.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.44 M
₹0
Charges Breakdown by Lending Institutions
- The Saraswat Co-Op Bank Ltd : 0.04 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Dec 2004 | The Saraswat Co-Op Bank Ltd | ₹0.44 M | Open |
How Many Employees Work at K Dass Pharma Distributors?
Unlock and access historical data on people associated with K Dass Pharma Distributors, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of K Dass Pharma Distributors, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped K Dass Pharma Distributors's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
